)
Edmund Graziani
CEO
Apertor Pharmaceuticals, Inc.
My current role focuses on leading the discovery and clinical development of novel molecular glues for therapeutic applications in oncology. Previously, I directed research programs at Pfizer and Wyeth involving (i) the synthetic biology of ‘beyond-rule-of-five’ compounds, (ii) conjugation of small molecules to antibodies to make antibody-drug conjugates (ADCs) for oncology indications at and co-invented an ADC that is advancing into clinical trials, and (iii) leading matrix teams to advance semi-synthetic natural products from early discovery to first-in-human (FIH) for programs in neuroscience (ILS-920 for ischemic stroke) and inflammation (MS/lupus).
Sessions
-
25-Jun-2026Theater 1Apertor Pharmaceuticals
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}